Drug Class Modifications Expected In Final Model Formulary, USP Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The number of designated drug classes will change based upon comments to the draft guidelines for Medicare formularies, USP exec says. However, “it’s too early to tell” if there will be more or fewer classes.
You may also be interested in...
USP Guidelines Meeting Will Hear Comments From Three Manufacturer Reps
Two representatives of newly merged Sanofi-Aventis and one from PhRMA are scheduled to present comments on proposed guidelines for Medicare drug formularies. AHIP will present health insurers' point of view, and PCMA will provide PBMs' response.
USP Guidelines Meeting Will Hear Comments From Three Manufacturer Reps
Two representatives of newly merged Sanofi-Aventis and one from PhRMA are scheduled to present comments on proposed guidelines for Medicare drug formularies. AHIP will present health insurers' point of view, and PCMA will provide PBMs' response.
USP Draft Medicare Formulary Sets 146 Drug Categories And Classes
The proposed total is greater than the number of classes desired by PBMs but falls below the threshold drug manufacturers are seeking. Medicare Part D plans following the model formulary would have to offer at least two drugs in each therapeutic category and pharmacologic class.